Sarah Ochsenbein
A5022492897- SARS-CoV-2 and COVID-19 Research
- Bacillus and Francisella bacterial research
- SARS-CoV-2 detection and testing
- Animal Virus Infections Studies
- Linguistics, Language Diversity, and Identity
- RNA Interference and Gene Delivery
- Viral gastroenteritis research and epidemiology
- Historical Linguistics and Language Studies
- Gender Studies in Language
University of Bern
2022-2024
Institute of Virology of the Slovak Academy of Sciences
2023
Federal Department of Home Affairs
2022
Abstract Variant of concern (VOC) Omicron-BA.1 has achieved global predominance in early 2022. Therefore, surveillance and comprehensive characterization advanced primary cell culture systems animal models are urgently needed. Here, we characterize recombinant spike gene mutants comparison with VOC Delta well-differentiated human nasal bronchial epithelial cells vitro, followed by vivo fitness hamsters, ferrets hACE2-expressing mice, immunized hACE2-mice. We demonstrate a spike-mediated...
Approved vaccines are effective against severe COVID-19, but broader immunity is needed new variants and transmission. Therefore, we developed genome-modified live-attenuated (LAV) by recoding the SARS-CoV-2 genome, including 'one-to-stop' (OTS) codons, disabling Nsp1 translational repression removing ORF6, 7ab 8 to boost host immune responses, as well spike polybasic cleavage site optimize safety profile. The resulting OTS-modified LAVs, designated OTS-206 OTS-228, genetically stable can be...
Abstract Variant of concern (VOC) Omicron-BA1 has achieved global predominance in early 2022. Therefore, surveillance and comprehensive characterization Omicron-BA.1 advanced primary cell culture systems multiple animal models is urgently needed. Here, we characterized recombinant spike gene mutants comparison with VOC Delta well-differentiated human nasal bronchial epithelial cells vitro, followed by vivo fitness naïve hamsters, ferrets hACE2-expressing mice, immunized hACE2-mice. We...
<title>Abstract</title> Vaccines are the most effective measure against COVID-19. However, novel and highly efficacious vaccines with simplified administration broad immunogenicity, providing systemic mucosal immunity needed. Here, we show development of live-attenuated (LAV) based on (i) recoding SARS-CoV-2 genome to enrich for "one-to-stop" (OTS) codons, (ii) facilitating host responses by disabling non-structural-protein-1 (Nsp1) mediated translational repression, deletion open reading...